The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Michael Hyman, Theodore Willis Laetsch, Shivaani Kummar, Steven G. DuBois, Anna F. Farago, Alberto S. Pappo, George D. Demetri, Wafik S. El-Deiry, Ulrik Niels Lassen, Afshin Dowlati, Marcia S. Brose, Valentina Boni, Brian Turpin, Ramamoorthy Nagasubramanian, Scott Cruickshank, Michael Craig Cox, Nora C. Ku, Douglas S. Hawkins, David S. Hong, Alexander E. Drilon
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas Southwestern Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Massachusetts General Hospital, St. Jude Children's Research Hospital, Harvard University, Fox Chase Cancer Center, Rigshospitalet, University Hospitals Cleveland Medical Center, Abramson Cancer Center, University of Pennsylvania, Hospital Universitario HM Sanchinarro, Cincinnati Children's Hospital Medical Center, Nemours Children's Clinic, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4245849692